Robotic Surgery for Biliary Tract Cancer

被引:13
|
作者
Kone, Lyonell B. [1 ]
Bystrom, Philip V. [1 ]
Maker, Ajay V. [2 ]
机构
[1] Univ Illinois, Metropolitan Grp Hosp, Chicago, IL 60607 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
关键词
cholangiocarcinoma; gallbladder cancer; robotic surgery; biliary tract cancer; klatskin tumor; minimally invasive surgery; HILAR CHOLANGIOCARCINOMA; GALLBLADDER CANCER; RADICAL RESECTION; OUTCOMES;
D O I
10.3390/cancers14041046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Complete surgical resection of biliary tract cancer provides the best chance at long-term survival. These surgeries are complex and can be associated with high morbidity and prolonged recovery. Minimally invasive approaches have been shown to improve some of these outcomes in other cancers. However, there is a paucity of data in biliary cancer, and even less is known about the outcomes of surgery utilizing a robotic platform. The present review reports the pooled outcomes of robotic surgery for 259 patients with biliary tract cancer. These outcomes are often equivalent to or improved compared to contemporary data on open surgery. The published data lack prospective or randomized studies. Thus, to evaluate any of the potential benefits of robotic surgery for biliary tract cancer, higher-quality studies are needed. Biliary tract cancer consists of cholangiocarcinoma (CC) and gallbladder cancer (GBC). When resectable, surgery provides the best chance at long-term survival. Unfortunately, surgery for these tumors is associated with long operative times, high morbidities, and prolonged hospital stays. Minimally invasive surgery has been shown to impact selected outcomes, including length of stay, in other diseases, and robotic surgery may offer additional advantages compared to laparoscopic surgery in treating bile duct cancers. This is a systematic review of robotic surgery for biliary tract cancer. Predetermined selection criteria were used to appraise the literature. The PRISMA guidelines were followed. In total, 20 unique articles with a total of 259 patients with biliary tract cancer undergoing robotic surgery met the inclusion criteria. For CC and GBC, respectively, the weighted average operative time was 401 and 277 min, the estimated blood loss was 348 and 260 mL, the conversion rate to open was 7 and 3.5%, the all-cause morbidity was 52 and 9.7%, the major morbidity was 12 and 4.4%, the perioperative mortality was 1.4 and 0%, the length of stay was 15 and 4.8 days, the positive margin rate was 27 and 9%, and the number of lymph nodes retrieved was 4.2 and 8. Robotic surgery for biliary tract cancer appears non-inferior to open surgery when compared to the published contemporary data. However, the current literature on the topic is of low quality, and future prospective/randomized studies are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Biliary tract cancer prognostic and predictive genomics
    Mondaca, Sebastian
    Nervi, Bruno
    Pinto, Mauricio
    Abou-Alfa, Ghassan K.
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (04)
  • [32] Innovations in surgery for gallbladder cancer: A review of robotic surgery as a feasible and safe option
    Mellado, Sebastian
    Chirban, Ariana M.
    Shapera, Emanuel
    Rivera, Belen
    Panettieri, Elena
    Vivanco, Marcelo
    Conrad, Claudius
    Sucandy, Iswanto
    Vega, Eduardo A.
    AMERICAN JOURNAL OF SURGERY, 2024, 233 : 37 - 44
  • [33] Immunotherapy of biliary tract cancer
    Chai, Yi
    TUMOR BIOLOGY, 2016, 37 (03) : 2817 - 2821
  • [34] Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications
    Lee, Sang-Hoon
    Song, Si Young
    CANCERS, 2024, 16 (09)
  • [35] Molecular-driven treatment for biliary tract cancer: the promising turning point
    Persano, Mara
    Puzzoni, Marco
    Ziranu, Pina
    Pusceddu, Valeria
    Lai, Eleonora
    Pretta, Andrea
    Donisi, Clelia
    Pinna, Giovanna
    Spanu, Dario
    Cimbro, Erika
    Parrino, Alissa
    Liscia, Nicole
    Mariani, Stefano
    Dubois, Marco
    Migliari, Marco
    Scartozzi, Mario
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1253 - 1264
  • [36] Biliary tract cancer incidence in the United StatesDemographic and temporal variations by anatomic site
    Castro, Felipe A.
    Koshiol, Jill
    Hsing, Ann W.
    Devesa, Susan S.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (07) : 1664 - 1671
  • [37] Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives
    Filippi, Roberto
    Lombardi, Pasquale
    Quara, Virginia
    Fenocchio, Elisabetta
    Aimar, Giacomo
    Milanesio, Michela
    Leone, Francesco
    Aglietta, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (17) : 2121 - 2137
  • [38] Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer
    Christensen, Troels D.
    Maag, Emil
    Larsen, Ole
    Feltoft, Claus L.
    Nielsen, Kaspar Rene
    Jensen, Lars Henrik
    Leerhoy, Bonna
    Hansen, Carsten P.
    Chen, Inna M.
    Nielsen, Dorte L.
    Johansen, Julia S.
    JHEP REPORTS, 2023, 5 (03)
  • [39] Biliary Tract Cancer: Current Medical Treatment Strategies
    Oneda, Ester
    Abu Hilal, Mohammed
    Zaniboni, Alberto
    CANCERS, 2020, 12 (05)
  • [40] Prognostic significance of tumor budding in biliary tract cancer
    Regmi, Parbatraj
    Paudyal, Aliza
    Paudyal, Pranita
    Hu, Hai-Jie
    Liu, Fei
    Ma, Wen-Jie
    Jin, Yan-Wen
    Li, Fu-Yu
    EJSO, 2022, 48 (01): : 160 - 168